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Abstract: Cardiovascular morbidity and mortality are enhanced in rheumatoid arthritis, which 
might be due to an increased prevalence of cardiovascular risk factors such as dyslipidemia. 
The dyslipidemia observed in RA appears to be dependent on disease activity, ie, a higher 
disease activity is associated with lower total cholesterol levels and even more depressed high 
density lipoprotein levels, leading to a higher (ie, unfavorable) atherogenic index. It appears 
that this dyslipidemia is already present long before the clinical onset of rheumatoid arthritis. 
Antirheumatic drug treatment with disease modifying antirheumatic drugs as well TNF-blocking 
agents has, in general, favorable, albeit moderate, effects on the lipid proﬁ  le. Therefore, it is 
unlikely that the observed beneﬁ  cial effects of antirheumatic drug treatment on cardiovascular 
morbidity and cardiovascular mortality in rheumatoid arthritis is mediated through effects on 
the lipid metabolism. Management of dyslipidemia in rheumatoid arthritis should be part of 
a general cardiovascular risk management. Hence, in addition to the assessment of the lipid 
proﬁ  le, other cardiovascular risk factors should be determined and appropriate treatment 
installed when indicated. Lower treatment thresholds should be considered in view of the 
enhanced cardiovascular risk in rheumatoid arthritis and guidelines should be developed based 
on epidemiological data.
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Introduction
Rheumatoid arthritis (RA), a chronic inﬂ  ammatory joint disease of unknown etiology, 
affects approximately one percent of the general population (Lems and Dijkmans 2000) 
Estimated standardized mortality ratio’s associated with RA range from 1.3 to 3.0 (Van 
Doornum et al 2002; Goodson and Solomon 2006). This increased mortality is largely 
attributable to cardiovascular disease (CVD), particularly coronary atherosclerosis 
(Solomon et al 2003; Maradit-Kremers, Crowson et al 2005). The cardiovascular 
morbidity found in RA patients appears to be increased by twofold or more compared 
to the general population (age and sex matched).
This increased cardiovascular risk in RA patients could have several causes. Firstly, 
the prevalence of new or established cardiovascular risk factors, such as dyslipidemia, 
diabetes mellitus, hypertension, higher body mass index (BMI), higher waist to hip-ratio 
or impaired physical ﬁ  tness, might be increased (Pincus and Callahan 1986; Dessein 
et al 2005; Goodson and Solomon 2006). Secondly, undertreatment of risk factors may 
play a role (Redelmeier et al 1998; Boers et al 2004). Finally, RA itself, particularly its 
chronic inﬂ  ammatory component, could be an independent cardiovascular risk factor 
(Maradit-Kremers, Nicola et al 2005).
Recently, new data on dyslipidemia in RA have been published which changed 
our insights about the lipid proﬁ  le in RA. In this article, the current literature about 
dyslipidemia in RA will be reviewed with a focus on the more recent papers as well as 
a brief overview of the management modalities for RA and the effects of antirheumatic Vascular Health and Risk Management 2007:3(6) 846
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drugs on the lipid proﬁ  le. Finally, treatment directions for 
dyslipidemia in RA will be discussed. The relevant literature 
was retrieved from a PubMed literature search using “rheu-
matoid arthritis” as one term and cholesterol, dyslipidemia 
and lipid proﬁ  le as the other terms. Moreover, citations from 
the retrieved articles for additional studies were scanned.
The lipid proﬁ  le in rheumatoid 
arthritis
It is known that increased levels of total cholesterol (TC), 
low-density-lipoprotein (LDL)-cholesterol (LDL-C) and a 
decreased level of high-density lipoprotein (HDL) cholesterol 
(HDL-C) are associated with an increased incidence of car-
diovascular disease in the general population. The available 
literature on lipid proﬁ  les in patients with RA is contradictory. 
There have been studies reporting either increased, decreased 
or similar levels for TC, LDL-C and HDL-C in comparison 
to control subjects (Heldenberg et al 1983; Lorber et al 1985; 
Lakatos and Harsagyi 1988; Kavanaugh 1994; Asanuma 
et al 1999).The discrepancies in the lipid values observed 
in the various studies might be due to differences in studied 
populations as well as in disease activity. There have been a 
few reports on lipid levels and their association with disease 
activity. One cross-sectional study in 28 patients with RA, 
with a mean disease duration of 7 years, demonstrated an 
inverse relationship between disease activity and lipid levels 
(Svenson et al 1987a), These ﬁ  ndings were recently conﬁ  rmed 
by a larger cross-sectional study in 204 patients with RA, 
demonstrating an inverse association between elevated CRP 
and HDL-C-levels (White et al 2006).
An important metabolic feature of RA is the catabolic 
state leading to loss of body cell mass due to a accelerated 
loss of skeletal muscle (Walsmith et al 2004). This is known 
as rheumatoid cachexia and important mediators are TNFα 
and other proinﬂ  ammatory enzymes. These mediators are 
also associated with lowered TC and HDL-C levels (Kotler 
2000), and as a higher disease activity in RA is accompanied 
with a higher TNF level this might explain the relationship 
between disease activity and lipid levels.
During the last decade interest has focused on apoli-
poprotein A-1 (apo A-1), apolipoprotein B (apo B) and 
lipoprotein(a) (Lp(a). Apo A-1 is the protein present on the 
HDL-C particles, whereas apo B is found on the LDL-C, 
very low density lipoprotein (VLDL) and chylomicrons 
particles. Hence, assessment of plasma apo A-1 and apo B 
allow an assessment of the total number of anti-atherogenic 
and atherogenic particles, respectively. Lp(a) is modiﬁ  ed 
form of LDL in which apo A-1 is bound to apo B.
There is some evidence that apo B might be a better pre-
dictor for cardiovascular events than LDL-C and that the apo 
B/apo A-1 ratio is an accurate risk factor for cardiovascular 
disease (Rader et al 1994; Walldius and Jungner 2006). In 
other words: Apo A-1 might protect against cardiovascular 
disease whereas apo B might increase the cardiovascular 
risk (Stampfer et al 1991; Sharrett et al 2001; Wallldius 
et al 2001).
One of the ﬁ  rst controlled studies reporting on apo-
lipoprotein levels in RA was performed in 42 untreated 
patients (mean disease duration 27 months) and 42 age- and 
sex-matched controls (Park et al 1999). The investigators 
found signiﬁ  cantly lower levels of apolipoprotein A1 and 
HDL-C in patients than in controls (128.5 mg/dL vs 151.8 
mg/dL, 41.2 mg/dL (1.07 mmol/L) vs 54.9 mg/dL (1.43 
mmol/L), respectively) and signiﬁ  cantly higher levels Lp(a) 
(27.1 vs 18.0 mg/dL, respectively). The ratios of apo B/apo 
A1, total cholesterol/HDL-cholesterol were signiﬁ  cantly 
higher in patients than in controls (0.82 vs 0.67, 4.4 vs 3.4, 
respectively). CRP levels had an inverse correlation with 
apolipoprotein A1 and HDL-C indicating an adverse effect 
of disease activity on lipid proﬁ  le.
Lp (a) appears to have predictive value for cardiovascular 
disease in patients with hypercholesterolemia (Cantin et al 
1998). Several earlier studies showed signiﬁ  cantly lower 
Lp(a) levels in RA patients and a signiﬁ  cant association with 
acute phase response (Rantapaa-Dahlqvist et al 1999). How-
ever, a later study found no signiﬁ  cant elevation of Lp(a) in 
RA patients, nor a signiﬁ  cant relationship between Lp(a) and 
the acute phase response (Lee et al 2000). Altogether, Lp(a) 
determination in RA seems to be of limited value.
When does the dyslipidemia 
in RA start?
Altogether, it appears that dyslipidemia is already present 
in early RA and the question raises whether or not this phe-
nomenon starts in the preclinical phase of RA. Hence, we 
investigated the lipid proﬁ  le over time and its relationship 
with inﬂ  ammation and serological markers, in subjects who 
later developed RA (Van Halm, Nielen et al 2006).
The lipid proﬁ  le was determined in 1078 serial blood 
bank samples, of 79 blood donors who later developed RA. 
These samples were compared with 1071 control samples of 
unselected blood donors, matched for age and sex.
The samples of future RA patients displayed, on average, 
4% higher TC, 9% lower HDLc, 17% higher triglyceride 
and 6% higher apo B levels compared to matched controls 
(p  0.05), at least ten years before the onset of symptoms.Vascular Health and Risk Management 2007:3(6) 847
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Although the differences in the various lipid values were 
small they have clinical relevance, in the light of results from 
other studies (Menotti and Lanti 2003; Sprecher et al 2003; 
Menotti et al 2004). For instance, in a placebo controlled 
study with ﬁ  brates, the differences of the lipid values between 
the active treatment and the placebo group were similar to 
the found differences in the present study and the individu-
als treated with ﬁ  brates had ultimately a more than 20% risk 
reduction for CVD (Rubins et al 1999).
As inﬂ  ammation only explained a small part of the 
observed differences in lipids between the persons who later 
develop RA and the controls we hypothesized that a less 
favorable lipid proﬁ  le might be related to the development 
of RA by a common or linked background. This could be a 
socio-economic (including dietary) or a genetic background. 
Alternatively, lipids might modulate the susceptibility to the 
development of inﬂ  ammatory diseases such as RA.
Subfractions and functional 
properties of lipid particles
Proton nuclear magnetic resonance spectroscopy (NMR) 
quantifies subclasses of lipoproteins, lipid content and 
average particle size. LDL is divided in to three classes 
(LDL-1–LDL-3), and HDL into ﬁ  ve classes of increasing 
particle size.
Hurt-Camejo et al demonstrated in a small controlled 
study signiﬁ  cantly higher levels of small dense (eg, more 
atherogenic) LDL (LDL-1) and signiﬁ  cantly lower levels of 
small dense HDL (HDL-2) in 31 RA patients and 28 sex- and 
age matched control subjects (Hurt-Camejo et al 2001). 
Concomitant “normal” LDL levels were lower in the RA 
patients whereas HDL levels were similar between the two 
groups. The observed rise of small dense LDL is important, 
in view of its association with cardiovascular disease in the 
general population.
The observed rise of small dense LDL might be due to 
increased levels of secretory group IIa phospholipase A2, 
an acute phase protein and an independent cardiovascular 
risk factor.
Another group looked at the function of HDL. Athero-
sclerosis starts when LDL inﬁ  ltrates the artery wall and 
is oxidized by reactive oxygen species to oxidized LDL 
(ox-LDL). Ox-LDL leads to phospholipid release, activating 
endothelial cells, thereby initiating an inﬂ  ammatory process 
which leads to the formation of foam cells and subsequent 
fatty streaks. Normal HDL exerts its antiatherogenic role by 
protecting LDL from oxidation (Ansell et al 2004) in addition 
to the inhibition of the expression of adhesion molecules 
and its role in the reverse cholesterol transport. This anti-
inﬂ  ammatory HDL can be distinguished from the so-called 
proinﬂ  ammatory HDL which does have these properties and 
actually may promote inﬂ  ammation (Navab et al 2001).
Recently, McMahon and colleagues showed that proinﬂ  am-
matory HDL was detected more often in RA patients (n = 48) 
than in control subjects,( n = 72), ie, 20% versus 4% respectively 
(McMahon et al 2006). As the rate in RA was approximately 
half of that was observed in patients with systemic lupus 
erythematosus proinﬂ  ammatory HDL might be a novel bio-
marker for the increased atherosclerotic risk in RA.
Management of rheumatoid arthritis
The management of RA consists of co-ordinated multidis-
ciplinary care, eg, with physical and occupational therapy 
and drug treatment. Successful treatment to limit joint dam-
age and functional loss requires early diagnosis and timely 
initiation of disease-modifying agents.
The pain in RA is caused by joint inﬂ  ammation and 
therefore non-steroidal anti-inﬂ  ammatory drugs (NSAIDs) 
are preferred over analgesics for pain management, in view 
of their anti-inﬂ  ammatory effects (American College of 
Rheumatology Subcommittee on Rheumatoid Arthritis 
2002). Analgesics may be added when NSAIDs alone are not 
enough for pain relief. However, these agents do not change 
the course of the disease, nor do they prevent joint damage. 
Therefore, patients with persisting disease activity require 
(early) treatment with disease modifying antirheumatic drugs 
(DMARDs). Evidence is accumulating that DMARDs can 
reduce or prevent joint destruction (Fries 2000). Active RA 
may cause irreversible joint destruction in the ﬁ  rst months 
of the disease and therefore DMARDs should be initiated 
early in those patients with active disease, ie, persisting joint 
pain, morning stiffness or fatigue, active arthritis or persisting 
elevation of the CRP or ESR. In general, early application 
of DMARDs implies initiating treatment within several 
weeks after the ﬁ  rst visit to the rheumatologist. Conventional 
DMARDs include methotrexate, leﬂ  unomide, sulphasalazine 
and hydroxychloroquine. Methotrexate is considered the 
drug of choice with a better long-term efﬁ  cacy than the other 
conventional DMARDs (Rau 2000). Several investigations 
have demonstrated that combination DMARD therapy might 
be more effective than mono-DMARD therapy in patients 
with early disease (Boers 2001). The place of corticosteroids 
is a continuing matter of debate in view of their side effects, 
particularly with long-term use. There is no doubt that 
corticosteroids rapidly and effectively suppress inﬂ  ammation 
in RA and their use might be justiﬁ  ed for short-term therapy, Vascular Health and Risk Management 2007:3(6) 848
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eg, for “bridging therapy” between the period between initia-
tion and response to DMARD therapy (Kirwan 2001).
TNFα is a pivotal cytokine in the pathogenesis in RA and 
TNFα blockade was shown to be very effective are rapid in 
controlling disease activity. TNFα antagonists, frequently 
in combination with methotrexate, appear to be the most 
effective antirheumatic drugs and the safety data available 
so far do not indicate major safety problems.
Presently, three anti-TNFα blockers are available for 
clinical use. Inﬂ  iximab is a chimeric mouse/human anti-
TNFα monoclonal antibody and binds to soluble as well 
as membrane-bound TNFα. Inﬂ  iximab is intravenously 
administered and after the initial infusion it is given at two, 
six and then every 8 weeks thereafter. Etanercept consists of 
two human TNFα receptors linked to each other and binds to 
circulating as well as cell-bound TNFα molecules. Etanercept 
is given subcutaneously once or twice weekly. Adalimumab 
is a human immunoglobulin (Ig) G1 antibody and adminis-
tered subcutaneously once every two weeks.
Antirheumatic treatment and
lipid proﬁ  le
Disease modifying antirheumatic drugs
A 9 month follow-up study in 11 patients with RA 
demonstrated normalisation of the lipid levels during anti-
rheumatic treatment after 9 months (Svenson et al 1987b). 
This was conﬁ  rmed by a larger uncontrolled investigation 
in 42 patients (Park et al 2002). The majority of responding 
patients were treated with methotrexate, and approximately 
50% received low-dose prednisolone. In the responders, 
HDL-C levels increased by 21%, apoA-I levels increased by 
23% and the ratio TC/HDL-C decreased by 9%. Recently, 
another uncontrolled investigation showed similar ﬁ  ndings 
(Georgiadis et al 2006).
Until recently, no randomized investigations studying 
the effect of antirheumatic treatment (including corticoste-
roids) on lipid proﬁ  le have been reported in patients with 
early RA. Therefore, we studied the effects of combination 
treatment with prednisolone on total and high-density lipo-
protein (HDL) cholesterol levels in patients with RA and 
the relationship between lipid levels and disease activity 
(Boers et al 2003). Total and HDL cholesterol levels were 
determined in stored samples from a previously conducted, 
56-week multicenter trial among patients with early RA 
investigating the value of intensive combination therapy 
(COBRA); the combination of sulfasalazine, methotrexate 
(stopped at 40 weeks) and prednisolone (initially 60 mg/day, 
tapered in 6 weekly steps to 7.5 mg/day and stopped after 
28 weeks) was compared to sulfasalazine alone (Boers 
et al 1997). Contrary to expectations, both total and HDL 
cholesterol were decreased in these patients with active RA 
at baseline, and increased on antirheumatic therapy. We 
found that combination therapy with prednisolone rapidly 
improved the atherogenic index (total/HDL cholesterol), 
an important prognostic cardiovascular risk factor. Early 
antirheumatic and especially corticosteroid (combination) 
treatment may improve cardiovascular risk in RA, and it 
appears that the use of corticosteroids is not a risk factor for 
cardiovascular disease in patients with RA, which is also 
suggested by other investigators (Wallberg-Jonsson 1997; 
Banks et al 2000).
Also lipid profiles in patients with established RA 
were assessed and we found that in established RA total 
cholesterol levels were only slightly raised, irrespective of 
disease activity. However, HDL cholesterol was signiﬁ  cantly 
higher in patients in remission than in patients with active 
disease.
As several studies suggested an association between 
hydroxychloroquine and lipid concentrations, Munro et al 
conducted a randomized one-year trial in patients with 
established RA where 100 patients were either treated with 
hydroxychloroquine (n = 51) or gold (n = (Munro et al 1997). 
This trial revealed a signiﬁ  cant rise of 15% and a decrease 
of 12% in HDL values in the patients treated with hydroxy-
chloroquine and gold, respectively, whereas there was no 
signiﬁ  cant change in TC levels.
Altogether, conventional DMARD (including corticoste-
roids) treatment has favorable effects on the lipid proﬁ  le. As 
there is mounting evidence for favorable effects of DMARD 
treatment on the cardiovascular risk in RA (Van Halm, 
Nurmohamed et al 2006) this might be (partially) mediated 
by favorable effects on the lipid proﬁ  le.
It is therefore of interest to investigate whether more 
powerful immunosuppressive agents, ie, biologicals have 
more profound effects on the lipid proﬁ  le in RA.
TNF-blocking agents
There is an increasing number of reports about the effects of 
treatment with tumor necrosis factor (TNF) blocking agents 
on the lipid proﬁ  le in RA patients with active disease. One of 
the ﬁ  rst reports, in a very limited number (n = 15) of patients 
with RA and psoriatic arthritis, showed that the lipid proﬁ  le 
changed to a more atherogenic proﬁ  le during treatment with 
inﬂ  iximab (Cauza et al 2002). Therefore, we prospectively 
investigated the effects of inﬂ  iximab, a drug with no known Vascular Health and Risk Management 2007:3(6) 849
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direct effects on the lipid proﬁ  le in a cohort of 69 patients with 
active, established RA during 6 weeks of inﬂ  iximab treatment 
(Vis et al 2005).The Disease Activity Index score (DAS-
28) was 5.9 at baseline and decreased to 4.6 after 2 weeks 
and further to 4.1 after 6 weeks. Total cholesterol level was 
5.2 mmol/L (200.2 mg/dL) at baseline and increased to 5.7 
mmol/L (219.5 mg/dL) (p  0.001) at 2 weeks, and was 5.6 
mmol/L ((215.6 mg/dL) (p  0.001 vs baseline) at Week 6. 
For HDL-cholesterol these values were 1.47 (56.60), 1.60 
(61.60) (p  0.001), and 1.59 (61.22) mmol/L (mg/dL) 
(p  0.001 vs baseline), respectively. Changes in disease 
activity were signiﬁ  cantly, inversely, associated with changes 
in total cholesterol and HDL-cholesterol levels. The athero-
genic index, however, remained constant. Corticosteroid 
use at baseline was associated with signiﬁ  cantly higher total 
cholesterol and HDL-cholesterol levels and a lower (more 
favorable) atherogenic index at baseline.
Seriolo et al (2006) determined lipid profiles after 
24 weeks anti-tnf treatment (ie, inﬂ  iximab or etanercept), 
in 34 patients with RA and also found enhanced TC and 
HDL-C levels whereas the atherogenic index remained 
constant. Another investigation, in 60 patients with inﬂ  am-
matory rheumatic diseases (ie, RA, ankylosing spondylitis 
or psoriatic arthritis) of which 24 had RA, demonstrated 
the persistence of modest increased HDL-C levels up to 
6 months after inﬂ  iximab treatment whereas the TC increase 
was transient (Spanakis et al 2006). In contrast, Kiortsis 
et al (2006) found no changes in lipid levels after one year 
inﬂ  iximab treatment in 50 RA patients, whereas Dahlqvist 
et al (2006) reported worsening of the lipid proﬁ  le after two 
years inﬂ  iximab treatment in 51 RA patients.
In a 48 week study of 80 inﬂ  iximab treated patients we 
found that lipid levels improved signiﬁ  cantly during inﬂ  ix-
imab therapy (Peters et al 2007). However, at the end of the 
study period all lipid changes, except for Apo A-1 levels, 
returned to baseline values. Longitudinal analyses revealed 
a signiﬁ  cant inverse association between lipid levels and 
disease activity and a signiﬁ  cant association between lipid 
levels and prednisone doses. Improvement according to the 
DAS-28 score of 1 point was associated with an increase 
of 0.016 mmol/L (0.62 mg/dL) in total cholesterol and 
0.045 mmol/L (1.74 mg/dL) in HDL cholesterol. In addi-
tion, 10 mg reduction of prednisone dose was associated 
with a decrease of 0.04 mmol/L (1.54 mg/dL) total- and 
0.16 mmol/L (6.18 mg/dL) HDL cholesterol. Altogether this 
study indicates that the fact that no changes in serum lipid 
levels were observed after 48 weeks of inﬂ  iximab treatment 
may be the result of opposing effects of changes in disease 
activity and changing (ie, decreasing) in prednisone dose on 
the lipid proﬁ  le.
In a two week placebo-controlled study with another TNF 
blocking agent, ie, adalimumab, the investigators observed, 
in the 33 adalimumab treated patients a 6% increase in TC 
levels (5.02 vs 4.70 at baseline) as well as a 15% increase in 
HDL-C levels (0.98 mmol/L (37.7 mg/dL) vs 0.86 mmol/L 
(33.1 mg/dL) at baseline) after two weeks treatment (Popa 
et al 2005). These signiﬁ  cant changes of lipid levels were 
also accompanied by a signiﬁ  cant decrease of the athero-
genic index.
Altogether these investigations with TNF blocking agents 
reveal a transient increase of TC and HDL-C mostly accom-
panied with improvement of the atherogenic index, during 
the ﬁ  rst few months of the TNF blocking agents. Thereafter 
the results become divergent between the studies. This might 
be due to differences in disease activity, (changes of) come-
dication, particularly prednisone, dietary intake and physical 
activity. Hence, future studies should appropriately address 
these potential confounders to reach valid conclusions.
Nevertheless, the lipid changes due to TNF-blocking 
agents appear to be moderate and the favorable effect of these 
agents on cardiovascular comorbidity are likely not be medi-
ated to a great extent by effects on lipid metabolism, but long-
term investigations are needed to investigate this topic.
Treatment of the atherogenic lipid 
proﬁ  le in RA
In view of the enhanced cardiovascular risk in RA, treat-
ment of dyslipidemia should be part of cardiovascular risk 
management in these patients.
First of all one should consider, for every RA patient, 
yearly screening of cardiovascular risk factors, ie, smoking, 
blood pressure, lipid proﬁ  le, plasma glucose, family history 
for cardiovascular disease, diet, alcohol intake, physical 
activity, body mass index, waist/hip ratio. Then, the 10 year 
risk cardiovascular disease can be assessed by using a risk 
function calculator, eg, the Framingham risk score, which 
is indicative for targeted risk factor reduction. For instance, 
several guidelines recommend a targeted risk factor approach 
for a 10 year CVD risk above 20% for patients without 
evidence for prior CVD.
For patients with a history of veriﬁ  ed CVD guidelines 
for secondary prevention should be followed.
However, these risk function calculations (functions) are 
based on the general population and cardiovascular risk factor 
functions for RA are not available. In view of the enhanced 
CVD risk in RA one could consider lower thresholds for Vascular Health and Risk Management 2007:3(6) 850
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targeted risk function reduction or multiply the 10 year risk 
by two.
Alternatively, as the risk in RA might be comparable to 
that of diabetes one could adopt similar treatment thresholds 
for risk factor reduction as in diabetes, eg, treatment with 
statins when LDL-C is above 2.5 mmol/L (96.3 mg/dL) and 
or treatment with antihypertensive agents with a systolic blood 
pressure above 140 mmHg. Particularly, statins are of interest 
in view of their anti-inﬂ  ammatory properties in addition to 
their cholesterol lowering effects, and a recent trial showed 
a moderate disease reduction in patients with active RA 
(McCarey et al 2004). Finally, in view of the clear relationship 
between diseased activity and cardiovascular disease in RA a 
tight disease control is mandatory. This will also have some, 
albeit moderate, (favorable) effects on the lipid proﬁ  le.
Discussion and recommendations
Recent research has shown that systemic inﬂ  ammation plays 
a pivotal role in the development of atherosclerosis. Hence, 
inﬂ  ammation might explain the increased cardiovascular 
risk in RA patients (Sattar et al 2003). In addition, inﬂ  am-
mation leads to pro-atherogenic changes of the lipoprotein 
metabolism and an increased disease activity is associated 
with lower TC levels and even more depressed HDL-C levels 
and lowered apo A1 levels.
Conventional DMARD treatment has beneﬁ  cial effects 
on the lipid proﬁ  le in RA and it is tempting to speculate that 
the favorable effect of DMARD treatment on the cardiovas-
cular morbidity and cardiovascular mortality in RA might 
be partially mediated by this mechanism.
It was expected that the effects of TNF-blocking therapy 
on the lipid proﬁ  le would be more pronounced than that of 
DMARD treatment but also TNF blocking therapy induces 
not more than moderate changes of the lipid proﬁ  le. More-
over, some studies indicate that these favorable changes level 
off after the ﬁ  rst few months of TNF blocking therapy, but 
favorable effects might be masked by changes in comedica-
tion, particularly corticosteroids. We found that lowering the 
prednisone dose results in a decreasing TC, predominantly 
due to a lower HDL-C resulting in a higher atherogenic index 
(as the effect on total cholesterol was less pronounced). Vice 
versa, increasing the prednisone dose might have favorable 
effects on the lipid proﬁ  le. Nevertheless, it is not known 
whether or not this beneﬁ  cial effect is ultimately offset by 
other cardiovascular side effects of long-term prednisone 
use, as insulin resistance and hypertension.
Even though the observed differences of DMARD 
treatment and TNF- blockers on the lipid proﬁ  le are small they 
might have clinical relevance, eg, The Lipid Research Clinics 
Coronary Primary Prevention Trial (LRC-CPPT) as well as the 
Framingham Study demonstrate that a 0.026 mmol/L(1 mg/dL) 
increment of baseline HDL cholesterol is associated with an 
approximately 3.5% risk reduction for coronary heart disease 
(The Framingham Study 1978; Gordon et al 1986). Another 
study performed by Rubins et al revealed that a 6% increase 
in HDL cholesterol is associated with an absolute risk reduc-
tion of 4.4% of death from coronary heart disease or non-fatal 
infarction (Rubins et al 1999).
Whether or not these moderate effects can explain the 
favorable effect of TNF-blocking therapy on cardiovascular 
morbidity and mortality observed in the literature, (Jacobsson 
et al 2005, 2006) remains to be established by long-term 
investigations.
Management of dyslipidemia should considered as a 
part of cardiovascular risk management in RA patients. It 
is evident that tight disease control lowers the cardiovas-
cular risk in RA and may have also some beneﬁ  cial effects 
on the lipid proﬁ  le. In addition, cardiovascular risk factor 
screening and appropriate treatment is necessary. In view 
of the enhanced cardiovascular risk in RA lower treatment 
thresholds should be considered but presently precise guide-
lines are lacking and need to come from currently conducted 
epidemiological investigations. Until these are available a 
pragmatic approach could be adopted, eg, by adjusting the, 
for the general population available, cardiovascular risk 
score functions.
Acknowledgment
I gratefully acknowledge Prof Dr. Y.M. Smulders for his 
advice and critical reading of the manuscript.
References
American College of Rheumatology Subcommittee on Rheumatoid Arthritis. 
2002. Guidelines for the management of rheumatoid arthritis: 2002 
update. Arthritis Rheum, 46:328–46.
Ansell BJ, Navab M, Watson KE, et al. 2004. Anti-inﬂ  ammatory properties 
of HDL. Rev Endocr Metab Disord, 5:351–8.
Asanuma Y, Kawai S, Aoshima H, et al. 1999. Serum lipoprotein(a) and 
apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. 
Arthritis Rheum, 42:443–7.
Banks M, Flint J, Bacon PA, et al. 2000. Rheumatoid arthritis is an inde-
pendent risk factor for ischaemic heart disease [abstract]. Arthritis 
Rheum, 43 (Suppl) 9:S385.
Boers M, Verhoeven AC, Markusse HM, et al. 1997. Randomised com-
parison of combined step-down prednisolon, methotrexate and sul-
phasalazine with sulphasalazine alone in early rheumatoid arthritis. 
Lancet, 350:309–18.
Boers M. 2001. Rheumatoid arthritis: Treatment of early disease. Rheum 
Dis Clin North Am, 27:405–14.
Boers M, Nurmohamed MT, Doelman CJ, et al. 2003. Inﬂ  uence of glucocor-
ticoids and disease activity on total and high density lipoprotein choles-
terol in patients with rheumatoid arthritis. Ann Rheum Dis, 62:842–5.Vascular Health and Risk Management 2007:3(6) 851
Dyslipidemia and rheumatoid arthritis
Boers M, Dijkmans B, Gabriel S, et al. 2004. Making an impact on mortality 
in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis 
Rheum, 50:1734–9.
Cantin B, Gagnon F, Moorjani S, et al. 1998. Is lipoprotein(a) an independent 
risk factor for ischemic heart disease in men? The Quebec Cardiovas-
cular Study. J Am Coll Cardiol, 31:519–25.
Cauza E, Cauza K, Hanusch-Enserer U, et al. 2002. Intravenous anti-
TNF-alpha therapy leads to elevated triglyceride and reduced HDL-
cholesterol levels in patients with rheumatoid and psoriatic arthritis. 
Wien Klin Wochenschr, 30:1004–7.
Dahlqvist SR, Engstrand S, Berglin E, et al. 2006. Conversion towards an 
atherogenic lipid proﬁ  le in rheumatoid arthritis patients during long-
term inﬂ  iximab therapy. Scand J Rheumatol, 35:107–11.
Dessein PH, Joffe BI, Veller MG, et al. 2005. Traditional and nontraditional 
cardiovascular risk factors are associated with atherosclerosis in RA. 
J Rheumatol, 32:435–42.
Fries JF. 2000. Current treatment paradigms in rheumatoid arthritis. Rheu-
matology, 39 (Suppl) 1:30–5.
Georgiadis AN, Papavasiliou EC, Lourida ES, et al. 2006. Atherogenic 
lipid proﬁ  le is a feature characteristic of patients with early rheumatoid 
arthritis: effect of early treatment – a prospective, controlled study. 
Arthritis Res Ther, 8:R82. Epub 2006 Apr 28.
Goodson NJ, Solomon DH. 2006. The cardiovascular manifestations of 
rheumatic diseases. Curr Opin Rheumatol, 18:135–40.
Gordon DJ, Knoke J, Probstﬁ  eld JL, et al. 1986. High-density lipoprotein 
cholesterol and coronary heart disease in hypercholesterolemic men: 
The Lipid Research Clinics Coronary Primary Prevention Trial. Cir-
culation, 74:1217–25.
Heldenberg D, Caspi D, Levtov O, et al. 1983. Serum lipids and lipoprotein 
concentrations in women with rheumatoid arthritis. Clin Rheumatol, 
2:387–91.
Hurt-Camejo E, Paredes S, Masana L, et al. 2001. Elevated levels of small, 
low-density lipoprotein with high afﬁ  nity for arterial matrix components 
in patients with rheumatoid arthritis: possible contribution of phospholi-
pase A2 to this atherogenic proﬁ  le. Arthritis Rheum, 44:2761–7.
Jacobsson LT, Turesson C, Gülfe A, et al. 2005. Low incidence of ﬁ  rst 
cardiovascular event in rheumatoid arthritis patients treated with TNF-
blockers. J Rheumatol, 32:1213–18.
Jacobsson LT, Turesson C, Nilsson JA, et al. 2006. Treatment with TNF-
blockers and mortality risk in patients with rheumatoid arthritis. Ann 
Rheum Dis, Dec 11; [Epub ahead of print].
Kavanaugh A. 1994. Dyslipoproteinaemia in a subset of patients with 
rheumatoid arthritis. Ann Rheum Dis, 53:551–2.
Kiortsis DN, Mavridis AK, Filippatos TD, et al. 2006. Effects of inﬂ  iximab 
treatment on lipoprotein proﬁ  le in patients with rheumatoid arthritis and 
ankylosing spondylitis. J Rheumatol, 33:921–3.
Kirwan JR. 2001. Systemic low-dose glucocorticoid in rheumatoid arthritis. 
Rheum Dis Clin North Am, 27:389–403.
Kotler DP. 2000. Cachexia. Ann Intern Med, 133:622–34.
Lakatos J, Harsagyi A. 1988. Serum total, HDL, LDL cholesterol and 
triglyceride levels in patients with rheumatoid arthritis. Clin Biochem, 
21:93–6.
Lee YH, Choi SJ, Ji JD, et al. 2000. Lipoprotein(a) and lipids in relation to 
inﬂ  ammation in rheumatoid arthritis. Clin Rheumatol, 19:324–25.
Lems WF, Dijkmans BAC. 2000. Rheumatoid arthritis: clinical aspects and 
its variants. In Firestein GS, Panayi GS, Wollheim FA, eds. Rheumatoid 
arthritis: new frontiers in pathogenesis and treatment. New York: Oxford 
University Press.p 213–25.
Lorber M, Aviram M, Linn S, et al. 1985. Hypocholesterolaemia and abnor-
mal high-density lipoprotein in rheumatoid arthritis. Br J Rheumatol, 
24:250–5.
Maradit-Kremers H, Crowson CS, Nicola PJ, et al. 2005. Increased unrecog-
nized coronary heart disease and sudden deaths in rheumatoid arthritis: 
a population-based cohort study. Arthritis Rheum, 52:402–11.
Maradit-Kremers H, Nicola PJ, Crowson CS, et al. 2005. Cardiovascular 
death in rheumatoid arthritis: a population-based study. Arthritis 
Rheum, 52:722–32.
McCarey DW, McInnes IB, Madhok R, et al. 2004. Trial of Atorvastatin 
in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-
controlled trial. Lancet, 363:2015–21.
McMahon M, Grossman J, FitzGerald J, et al. 2006. Proinﬂ  ammatory 
high-density lipoprotein as a biomarker for atherosclerosis in patients 
with systemic lupus erythematosus and rheumatoid arthritis. Arthritis 
Rheum, 54:2541–9.
Menotti A, Lanti M. 2003. Coronary risk factors predicting early and late 
coronary deaths. Heart, 89:19–24.
Menotti A, Kromhout D, Blackburn H, et al. 2004. Forty-year mortality from 
cardiovascular diseases and all causes of death in the US Railroad cohort 
of the Seven Countries Study. Eur J Epidemiol, 19:417–24.
Munro R, Morrison E, McDonald AG, et al. 1997. Effect of disease modi-
fying agents on the lipid proﬁ  les of patients with rheumatoid arthritis. 
Ann Rheum Dis, 56:374–7.
Navab M, Hama SY, Hough GP, et al. 2001. A cell-free assay for detecting 
HDL that is dysfunctional in preventing the formation of or inactivating 
oxidized phospholipids. J Lipid Res, 42:1308–17.
Park YB, Lee SK, Lee WK, et al. 1999. Lipid proﬁ  les in untreated patients 
with rheumatoid arthritis. J Rheumatol, 26:1701–4.
Park YB, Choi HK, Kim MY, et al. 2002. Effects of antirheumatic therapy 
on serum levels in patients with rheumatoid arthritis: a prospective 
study. Am J Med, 113:188–93.
Peters MJ, Vis M, van Halm VP, et al. 2007. Changes in lipid proﬁ  le during 
inﬂ  iximab treatment and corticosteroid therapy in rheumatoid arthritis. 
Ann Rheum Dis, Feb 21; Epub ahead of print.
Pincus T, Callahan L. 1986. Taking mortality in rheumatoid arthritis 
seriously – predictive markers, socioeconomic status and comorbidity. 
J Rheumatol, 13:841–5.
Popa C, Netea MG, Radstake T, et al. 2005. Inﬂ  uence of anti-tumour 
necrosis factor therapy on cardiovascular risk factors in patients with 
active rheumatoid arthritis. Ann Rheum Dis, 64:303–5.
Rader DJ, Hoeg JM, Brewer HB, Jr. 1994. Quantitation of plasma apoli-
poproteins in the primary and secondary prevention of coronary artery 
disease. Ann Intern Med, 120:1012–25.
Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Dahlen G. 1999. Lipoprotein 
(a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann 
Rheum Dis, 50:366–8.
Rau R. 2000. Methotrexate. In: Firestein GS, Panayi GS, Wollheim FA, 
eds. Rheumatoid arthritis: new frontiers in pathogenesis and treatment. 
Oxford (NY): Oxford University Press.p 337–50.
Redelmeier DA, Tan SH, Booth GL. 1998. The treatment of unrelated 
disorders in patients with chronic medical diseases. N Engl J Med, 
338:1516–20.
Rubins HB, Robins SJ, Collins D, et al. 1999. Gemﬁ  brozil for the secondary 
prevention of coronary heart disease in men with low levels of high-
density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein 
Cholesterol Intervention Trial Study Group. N Engl J Med, 341:410–18.
Sattar N, McCarey DW, Cappel H, et al. 2003. Explaining how ‘high-grade’ 
systemic inﬂ  ammation accelerates vascular risk in rheumatoid arthritis. 
Circulation, 108:2957–63.
Seriolo B, Paolino S, Sulli A, et al. 2006. Effects of anti-TNF-alpha treat-
ment on lipid proﬁ  le in patients with active rheumatoid arthritis. Ann 
N Y Acad Sci, 1069:414–19.
Sharrett AR, Ballantyne CM, Coady SA, et al. 2001. Coronary heart disease 
prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), 
apolipoproteins A-I and B, and HDL density subfractions: The Atheroscle-
rosis Risk in Communities (ARIC) Study. Circulation, 104:1108–13.
Solomon DH, Karlson EW, Rimm EB, et al. 2003. Cardiovascular 
morbidity and mortality in women diagnosed witch rheumatoid arthritis. 
Circulation, 107:1303–7.
Spanakis E, Sidiropoulos P, Papadakis J, et al. 2006. Modest but sustained 
increase of serum high density lipoprotein cholesterol levels in patients with 
inﬂ  ammatory arthritides treated with inﬂ  iximab. J Rheumatol, 33:2440–6.
Sprecher DL, Watkins TR, Behar S, et al. 2003. Importance of high-density 
lipoprotein cholesterol and triglyceride levels in coronary heart disease. 
Am J Cardiol, 91:575–80.Vascular Health and Risk Management 2007:3(6) 852
Nurmohamed
Stampfer MJ, Sacks FM, Salvini S, et al. 1991. A prospective study of 
cholesterol, apolipoproteins, and the risk of myocardial infarction. 
N Engl J Med, 325:373–81.
Svenson KLG, Lithell H, Hällgren, et al. 1987a. Serum lipoprotein in active 
rheumatoid arthritis and other chronic inﬂ  ammatory arthritides.I Rela-
tivity to inﬂ  ammatory activity. Arch Intern Med, 147:1912–16.
Svenson KLG, Lithell H, Hällgren, et al. 1987b. Serum lipoprotein in active 
rheumatoid arthritis and other chronic inﬂ  ammatory arthritides. Effects 
of anti-inﬂ  ammatory and disease-modifying drug treatment. Arch Intern 
Med, 147:1917–20.
The Framingham Study: Coronary risk handbook using HDL-cholesterol 
for persons over 50. 1978. Bethesda, National Heart, Lung and Blood 
Institute.
Van Doornum S, McGoll G, Wicks IP. 2002. Accelerated atherosclerosis: 
an extraarticular feature of rheumatoid arthritis. Arthritis Rheum, 
46:862–73.
Van Halm VP, Nielen MM, Nurmohamed MT, et al. 2006. Lipids and 
inﬂ  ammation – serial measurements of the lipid proﬁ  le of blood donors 
who later developed rheumatoid arthritis. Ann Rheum Dis, Jun 7; [Epub 
ahead of print].
Van Halm VP, Nurmohamed MT, Twisk JW, et al. 2006. Disease-modifying 
antirheumatic drugs are associated with a reduced risk for cardiovascu-
lar disease in patients with rheumatoid arthritis: a case control study. 
Arthritis Res Ther, Sep 20; 8:R151 [Epub ahead of print].
Vis M, Nurmohamed MT, Wolbink G, et al. 2005. Short term effects of 
inﬂ  iximab on the lipid Proﬁ  le in patients with rheumatoid arthritis. 
J Rheumatol, 32:252–5.
Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. 1997. Cardiovascularmor-
bidity and mortality in patients with seropositive rheumatoid arthritis 
in northern Sweden. J Rheumatol, 24:445–51.
Walldius G, Jungner I, Holme I, et al. 2001. High apolipoprotein B, 
low apolipoprotein A-I, and improvement in the prediction of fatal 
myocardial infarction (AMORIS study): a prospective study. Lancet, 
358:2026–33.
Walldius G, Jungner I. 2006. The apoB/apoA-I ratio: a strong, new risk factor 
for cardiovascular disease and a target for lipid-lowering therapy – a 
review of the evidence. J Intern Med, 259:493–519.
Walsmith J, Abad L, Kehayias J, Roubenoff R. 2004. Tumor necrosis 
factor-α production is associated with less body cell mass in women 
with rheumatoid arthritis. J Rheumatol, 31:23–9.
White D, Fayez S, Doube A. 2006. Atherogenic lipid proﬁ  les in rheumatoid 
arthritis. N Z Med, 119:U2125.